Physician profile
Eric A Camyre
NPI 1831326461
$25,843.14
in general payments reported to CMS, 2019-2025
67 companies · $4,068 in 2025
The $4,068 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,159 · 2020: $2,253 · 2021: $2,622 · 2022: $3,797 · 2023: $3,742 · 2024: $4,201 · 2025: $4,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $20.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,990.87 |
| Education | $20.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,195.99 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $2,670.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,174.55 | 2019-2025 | Airsupra, Breztri, Bevespi Aerosphere |
| Glaxosmithkline, LLC. | $1,977.22 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,493.70 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $1,261.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,177.12 | 2019-2025 | |
| Amgen INC. | $1,017.87 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $821.83 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Sanofi-Aventis U.S. LLC | $800.83 | 2019-2025 | |
| Abbott Laboratories | $631.94 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $621.32 | 2019-2025 | Spravato, Xarelto |
| Novartis Pharmaceuticals Corporation | $620.29 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $616.95 | 2021-2025 | |
| Astellas Pharma US INC | $589.71 | 2019-2025 | Veozah, Myrbetriq |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Camyre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.